World Hepatitis Day 2017

28th of July, 2017


World Hepatitis Day 2017: Eliminate Hepatitis

World Hepatitis Day, held on 28 July 2017, highlights the global initiative to eliminate viral hepatitis by 2030. To support the campaign, we have collated a Virtual Special Issue featuring a range of cutting-edge hepatitis research across several journals.

Viral hepatitis is an inflammation of the liver caused by viruses, which typically spread through infected drinking water or bodily fluids. The disease kills approximately 1.4 million people worldwide every year. About 325 million people are infected, of which 240 million suffer from chronic hepatitis B, while 80 million people have chronic hepatitis C. Staggeringly, 95% of those infected are unaware of their illness, and less than 1% access treatment.

Chronically infected patients who don't access appropriate diagnosis or treatment services could eventually develop cirrhosis, liver cancer or other liver diseases. In many cases, doctors can easily prevent the disease using vaccines, or treat it using antiviral drugs.

The World Health Organization's Global Strategy on Viral Hepatitis aims to eradicate the disease by 2030, and has spawned the NOhep campaign to raise publicity. The strategy provides a set of testing, prevention and treatment milestones for governments. If governments can meet these targets, then more people will be vaccinated and treated, resulting in a 65% drop in hepatitis deaths, and saving 7.1 million lives by 2030.

Tackling hepatitis involves scientists finding new ways to diagnose the disease and developing new vaccines and treatments. Their contribution is crucial to ending hepatitis. We want to highlight the rich array of key research taking place which aims to understand, detect and treat hepatitis. This Virtual Special Issue covers hepatitis diagnostics, vaccines, antiviral treatments, treatment resistance, clinical practice guidelines, awareness, prevalence, susceptibility and more. We'd like to invite scientists from this discipline to contribute their research to end hepatitis.

Selected articles

View Articles published in Clinical Microbiology and Infection

Clinical Microbiology and Infection

The added value of hepatitis E diagnostics in determining causes of hepatitis in routine diagnostic settings in the Netherlands
M.H.E. Doting, J. Weel, H.G.M. Niesters, A. Riezebos-Brilman, A. Brandenburg

Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study
I.T. Wu, T.H. Hu, C.H. Hung, S.N. Lu, J.H. Wang, C.M. Lee, C.H. Chen

Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection
J.A. Pineda, L.E. Morano-Amado, R. Granados, J. Macías, F. Téllez, M. García-Deltoro, M.J. Ríos, A. Collado, M. Delgado-Fernández, M. Suárez-Santamaría, M. Serrano, C. Miralles-Álvarez, K. Neukam

Awareness Campaign in (bio)Medical Students in Iran: a model for increasing the knowledge regarding hepatitis B and C
H. Karimi-Sari, M.E. Bayatpoor, S.M. Alavian

Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus
M. Puoti, P. Lorenzini, A. Cozzi-Lepri, A. Gori, C. Mastroianni, G. Rizzardini, G. Mazzarello, A. Antinori, A. d'Arminio Monforte, E. Girardi E; Icona Foundation Study Group.

Low and disparate seroprotection after pentavalent childhood vaccination in the Lao People's Democratic Republic: a cross-sectional study
K. Evdokimov, K. Sayasinh, P. Nouanthong, K. Vilivong, B. Samountry, D. Phonekeo, M. Strobel, F. Haegeman, P. Heimann, C.P. Muller, A.P. Black

View Articles published in International Journal of Infectious Diseases

International Journal of Infectious Diseases

Time to re-evaluate the effect of the adolescent booster of hepatitis B vaccine
E. Carmody

Dual sexual and drug-related predictors of hepatitis C incidence among sex workers in a Canadian setting: gaps and opportunities for scale-up of hepatitis C virus prevention, treatment, and care
S.M. Goldenberg, J. Montaner, M. Braschel, E. Socias, S. Guillemi, K. Shannon

Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study
M. Laguno, M.A. Von Wichmann, E. Van den Eynde, J. Navarro, C. Cifuentes, J. Murillas, S. Veloso, M. Martínez-Rebollar, J.M. Guardiola, A. Jou, J.L. Gómez-Sirvent, M. Cervantes, J.A. Pineda, S. López-Calvo, A. Carrero, M.L. Montes, E. Deig, A. Tapiz, J.D. Ruiz-Mesa, A. Cruceta, E. de Lazzari, J. Mallolas

View Articles published in Journal of Clinical Virology

Journal of Clinical Virology

Diagnostic performance of serological assays for anti-HBs testing: Results from a quality assessment program
Stijn Raven, Jeannine Hautvast, Jim van Steenbergen, Reinier Akkermans, Cas Weykamp, Francis Smits, Christian Hoebe, Ann Vossen.

Performance of HBsAg quantification assays for detection of Hepatitis B virus genotypes and diagnostic escape-variants in clinical samples
Vincent Thibault, Annabelle Servant-Delmas, Thoai Duong Ly, Anne-Marie Roque-Afonso, Syria Laperche.

A genotype independent, full-genome reverse-transcription protocol for HCV genotyping and resistance testingAndreas Walker, Matthias Bergmann, Jennifer Camdereli, Rolf Kaiser, Nadine Lübke, Jörg Timm.

View Articles published in Journal of Infection

Journal of Infection

Quasispecies characteristics in mother-to-child transmission of hepatitis B virus by next-generation sequencing
Guifeng Yang, Zhihua Liu, Juncheng Yang, Kangxian Luo, Ying Xu, Haitang He, Qunfang Fu, Shouyi Yu, Zhanhui Wang

Clinical and virological profiling of sporadic hepatitis E virus infection in China
Lin Wang, Lin Liu, Yongli Wei, Qianhui Wang, Qing Tian, Ling Wang, Hui Zhuang

Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones
Eisuke Murakami, Masataka Tsuge, Nobuhiko Hiraga, Hiromi Kan, Takuro Uchida, Keiichi Masaki, Takashi Nakahara, Atsushi Ono, Daiki Miki, Tomokazu Kawaoka, Hiromi Abe, Michio Imamura, Hiroshi Aikata, Hidenori Ochi, C. Nelson Hayes, Tomoyuki Akita, Junko Tanaka, Kazuaki Chayama

View Articles published in Diagnostic Microbiology and Infectious Disease

Diagnostic Microbiology and Infectious Diseases

New direct-acting antivirals for patients with chronic HCV infection: can we monitor treatment using an HCV core antigen assay?
R. Alonso, F. Pérez-García, D. Ampuero, E. Reigadas, E. Bouza

Discordant diagnostic results due to a hepatitis B virus T123A HBsAg mutant
C. Osiowy, K. Kowalec, E. Giles

Correlation of the content of hepatitis B core antigen in peripheral blood mononuclear cells with HBV virus load
Y. Peng, X. Xiong, X. Tong, M. Li, X. Yang, G. Hu, Y. Geng, J. Li

View Articles published in Journal of Hepatology

Journal of Hepatology

Visualization of hepatitis E virus RNA and proteins in the human liver
Daniela Lenggenhager, Jérôme Gouttenoire, Mohsen Malehmir, Marion Bawohl, Hanna Honcharova-Biletska, Susanne Kreutzer, David Semela, Jörg Neuweiler, Sandra Hürlimann, Patrick Aepli, Montserrat Fraga, Roland Sahli, Luigi Terracciano, Laura Rubbia-Brandt, Beat Müllhaupt, Christine Sempoux, Darius Moradpour, Achim Weber

Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses
Tania M. Welzel, Neeru Bhardwaj, Charlotte Hedskog, Krishna Chodavarapu, Gregory Camus, John McNally, Diana Brainard, Michael D. Miller, Hongmei Mo, Evguenia Svarovskaia, Ira Jacobson, Stefan Zeuzem, Kosh Agarwal.


Response to the Cochrane Systematic Review on DAA-Based Treatment of Chronic Hepatitis C
European Association for the Study of the Liver

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infectionPietro Lampertico, Kosh Agarwal, Thomas Berg, Maria Buti, Harry L.A. Janssen, George Papatheodoridis, Fabien Zoulim, Frank Tacke

Recommendations on Treatment of Hepatitis C 2016
European Association for the Study of the Liver

ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients
Luca S. Belli, Christophe Duvoux, Marina Berenguer, Thomas Berg, Audrey Coilly, Isabelle Colle, Stefano Fagiuoli,  Saye Khoo, Georges Philippe Pageaux, Massimo Puoti, Didier Samuel, Mario Strazzabosco


Edited by Thomas Berg and Xavier Forns, New Perspectives in HCV Infection, Volume 65, Issue 1, Supplement, Pages S1-S156 (October 2016)

View Articles published in Current Opinion in Virology

Current Opinion in Virology

Emerging concepts for the treatment of hepatitis delta
Menashe Elazar, Jeffrey S. Glenn

Novel viral and host targets to cure hepatitis B
Chunkyu Ko, Thomas Michler, Ulrike Protzer

View Articles published in Antiviral Research

Antiviral Research

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
Guangdi Li, Erik De Clercq

NK cell phenotypic and functional shifts coincide with specific clinical phases in the natural history of chronic HBV infection
Rik A. de Groen, Jun Hou, Gertine W. van Oord, Zwier M.A. Groothuismink, Marieke van der Heide, Robert J. de Knegt, André Boonstra

View Articles published in Microbial Pathogenesis

Microbial Pathogenesis

Complete genome sequencing and clinical analysis of intrahepatic hepatitis B virus cccDNA from HCC
Fengping Jiao, Lu Long, Shanlong Ding, Xiaomeng Xie, Le Jia, Fengmin Lu

View Articles published in Infection, Genetics and Evolution

Infection, Genetics and Evolution

Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C
Lucio Boglione, Jessica Cusato, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio

Tracing the epidemic history of hepatitis C virus genotypes in Saudi Arabia
Anis Khan, Mohammed Al Balwi, Latifah AlAyyar, Ibrahim AlAbdulkareem, Abdulkareem Albekairy, Abdulrahman Aljumah

View Articles published in Digestive and Liver Disease

Digestive and Liver Disease

Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel
Mauro Viganò, Carlo Federico Perno, Antonio Craxì, The AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party

Contribute your research to eliminate hepatitis: